Hi all,Two interesting analyses by two authors. One was extremely close to ourselves.Anyway, early last week I bought more options as the Black Scholes calculator said it was undervalued.Next Monday I will buy some more heads.The science is good and I can see it getting better, the mathematical studies are good.SP to increase as certain parameters have been dealt with !Plus gaining an ODD is a license to print money as so the studies suggest.In relation to Biogen "While BIIB105 lowered ATXN2 protein, it did not reduce neurofilament, which gives us confidence that BIIB105 did not slow the disease process,” said Stephanie Fradette, Pharm.D., Head of the Neuromuscular Development Unit at Biogen.Remember increased longevity with MND suggests neurofilament levels increase.Biogen also said " Additionally, BIIB105 did not demonstrate an impact on clinical outcome measures of function, breathing, and strength".In relation to Pharmaust An interim trial analysis showed stable blood levels of neurofilament light chain (NfL), a marker of nerve cell damage, in 11 of the 12 patients, suggesting “stabilized MND progression,” the company reported in August.Rates of disease progression in patients with Motor Neurone Disease (MND) / Amyotrophic Lateral Sclerosis (ALS) measured by changes in ALSFRS-R may be slowed by 58% for Cohort 2, when compared to an external control cohort (PRO-ACT database.Why wouldn't one buy ? Who is left in this market with an oral tablet with negligible side effects?https://www.sciencedirect.com/science/article/abs/pii/S1359644623003239https://www.linkedin.com/pulse/odds-ripple-effect-asx-biotech-prices-fda-incentives-big-baker-1cn0c?utm_source=share&utm_medium=member_android&utm_campaign=share_viahttps://alsnewstoday.com/news/fda-pharmaust-discuss-advance-monepantel-als-clinical-trials/https://*********.com.au/pharmaust-interim-phase-1-data-mpl-inhibit-motor-neurone-disease/
Thankyou Dr Thurn and (related team) for your hugely valuable input on securing this mammoth FDA approval.Kpax
- Forums
- ASX - By Stock
- PAA
- Ann: PharmAust receives Orphan Drug Designation for monepantel
Ann: PharmAust receives Orphan Drug Designation for monepantel, page-31
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
18.5¢ |
Change
0.005(2.78%) |
Mkt cap ! $89.95M |
Open | High | Low | Value | Volume |
18.5¢ | 19.0¢ | 18.5¢ | $111.6K | 601.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 169572 | 18.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
19.0¢ | 613756 | 10 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 169572 | 0.185 |
8 | 54129 | 0.180 |
4 | 344819 | 0.175 |
8 | 565800 | 0.170 |
4 | 385807 | 0.165 |
Price($) | Vol. | No. |
---|---|---|
0.190 | 613756 | 10 |
0.195 | 605600 | 8 |
0.200 | 231600 | 9 |
0.205 | 221875 | 2 |
0.215 | 178520 | 3 |
Last trade - 15.46pm 30/08/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |
The Watchlist
1CG
ONE CLICK GROUP LIMITED
Mark Waller, MD
Mark Waller
MD
Previous Video
Next Video
SPONSORED BY The Market Online